On March 31, 2020 Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") reported that it has fully placed the new shares from the capital increase resolved on March 30, 2020 of up to EUR 3,602,154.00 at a price of EUR 1.11 per new share (Press release, Epigenomics, MAR 31, 2020, View Source [SID1234556024]). Accordingly, the Company’s share capital will be increased from currently EUR 43,527,692.00 by EUR 3,602,154.00 to EUR 47,129,846.00 by issuing up to 3,602,154 new registered no par value shares of the Company against cash contributions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The new shares were fully subscribed by institutional investors from Germany and the U.S.A. by way of a private placement with the exclusion of the shareholders’ subscription rights and carry full dividend rights as of January 1, 2019.

The gross proceeds from the capital increase amount to approximately EUR 4.0 million.

Subject to the registration of the entry of the capital increase in the commercial register and any delays caused by the COVID 19 pandemic, the Company assumes that the admission of the new shares to the regulated market (Prime Standard) of the Frankfurt Stock Exchange will probably take place on or around April 3, 2020.

Epigenomics AG intends to use the net proceeds from the capital increase primarily to finance its ongoing operations.